Rakuten Medical
San Diego · Founded 2010
About Rakuten Medical
Rakuten Medical is a biotechnology company developing investigational cancer therapies based on its proprietary Alluminox platform. This platform integrates a drug, a device, and other components to deliver photoimmunotherapy, a treatment that combines a light-activated dye with a targeting agent to selectively destroy cancer cells. The company's lead asset, ASP-1929, is an antibody-dye conjugate currently approved in Japan for treating unresectable locally advanced or recurrent head and neck cancer. Rakuten Medical is conducting global clinical trials to evaluate the safety and efficacy of its therapies in combination with other treatments. The company also offers an Expanded Access Program to provide investigational products to patients with serious or life-threatening diseases who lack other treatment options. Rakuten Medical operates in multiple countries and focuses on developing new cancer treatments based on its Alluminox™ platform.
Company Facts
- Founded: 2010
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 101 – 250
- Estimated revenue: $10K – $50K
- Total funding: $837.6M
- Funding stage: Late Stage Venture
- Last round: Series F (Jan 2026)
- Website: https://rakuten-med.com
- Phone: +81 858 925-5619
Industries & Categories
Biotechnology, Health Care, Medical, Service Industry, Therapeutics
Investment Activity
- 1 exit(s)
Social Profiles
Canonical: https://fsome.com/organization/rakuten-medical-11562 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.